ZD1839

From WikiMD.org
Jump to navigation Jump to search

ZD1839

ZD1839 (pronounced as Zee-Dee-One-Eight-Three-Nine), also known as Gefitinib, is a drug used in the treatment of certain types of cancer. It is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase and is marketed by AstraZeneca under the trade name Iressa.

Etymology

The name ZD1839 is a unique identifier given by the pharmaceutical company AstraZeneca. The prefix "ZD" is a code used by the company for its drug development projects. The numbers "1839" do not have a specific meaning and are part of a sequential numbering system.

Usage

ZD1839 is primarily used in the treatment of non-small cell lung cancer. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This helps to stop or slow the spread of cancer cells.

Related Terms

Side Effects

Common side effects of ZD1839 include diarrhea, rash, acne, dry skin, nausea, vomiting, and loss of appetite. Serious side effects can include lung problems, liver problems, and eye problems. Patients should consult their healthcare provider for any side effects that are severe or do not go away.

Precautions

Before taking ZD1839, patients should inform their healthcare provider if they have lung disease, liver disease, or eye problems. It is also important to inform the healthcare provider of all the medications, vitamins, and herbal supplements being taken.

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski